Fecal Microbiota Transplantation As a Potential Treatment for Parkinson's Disease

Last updated: August 2, 2020
Sponsor: Soroka University Medical Center
Overall Status: Completed

Phase

2/3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03876327
0266-15-SOR
  • Ages > 50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

this pilot study aims to further explore the potential usage of Fecal microbiota transplantation in treating constipation and possibly also motor symptoms in Parkinson's disease (PD) patients, and to increase understanding of the potential relationship between the identities of intestinal microbial communities and PD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects aged > 50 years, diagnosed as suffering from PD and under follow up of theMovement Disorders Clinic in Soroka University Medical Center.

  • Subjects complaining of constipation .

  • Subjects who did not perform a screening colonoscopy for colon cancer.

  • Subjects who are clinically undertreated according to last Movement Disordersspecialist's impression at the clinic visit.

Exclusion

Exclusion Criteria:

  • Subjects who do not complain of constipation or seem clinically stable properlytreated pharmacologically.

  • Subjects who already underwent a screening colonoscopy for colon cancer.

  • Subjects who suffer from a cognitive decline and could not give their consent, orpatients who refuse to undergo a colonoscopy.

Study Design

Total Participants: 10
Study Start date:
August 19, 2015
Estimated Completion Date:
June 30, 2020

Study Description

Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms and Gastrointestinal dysfunction, in particular constipation, affects up to 80% of PD patients and may precede the onset of motor symptoms by years.

this study include one group of PD patients that will receive FMT. two other groups will serve as controls:

  1. PD patients that will not receive FMT

  2. healthy people who live with PD patients in the same house and share similar surrounding

Connect with a study center

  • Soroka Medical Center

    Be'er Sheva, 151
    Israel

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.